Talk:Pertuzumab: Difference between revisions

Content deleted Content added

Inline

Latest revision as of 18:49, 22 February 2024

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pertuzumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

This is the talk page for discussing improvements to the Pertuzumab article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

APHINITY confirmatory trial

APHINITY is the confirmatory trial for the September 2013 accelerated approval. Phase III Trial Results Confirm Adjuvant Pertuzumab Success in HER2+ Breast Cancer - Could mention in History or a new Clinical trials section ? - Rod57 (talk) 18:05, 20 March 2017 (UTC)[reply]

@@ Line 1: / Line 1: @@
 {{Reliable sources for medical articles}}
 {{Talk header}}
+{{WikiProject banner shell|class=Start|
-{{WikiProjectBannerShell|1=
-{{WikiProject Pharmacology |class=start |importance=Low}}
+{{WikiProject Pharmacology |importance=High}}
-{{WikiProject Medicine |class=start |importance=Low}}}}
+{{WikiProject Medicine |importance=Mid}}
+}}
 == APHINITY confirmatory trial  ==
-APHINITY is the confirmatory trial for the September 2013 [[accelerated approval]]. [http://www.targetedonc.com/news/phase-iii-trial-results-confirm-adjuvant-pertuzumab-success-in-her2-breast-cancer ''Phase III Trial Results Confirm Adjuvant Pertuzumab Success in HER2+ Breast Cancer''] - [[User:Rod57|Rod57]] ([[User talk:Rod57|talk]]) 18:03, 20 March 2017 (UTC)
+APHINITY is the confirmatory trial for the September 2013 [[accelerated approval]]. [http://www.targetedonc.com/news/phase-iii-trial-results-confirm-adjuvant-pertuzumab-success-in-her2-breast-cancer ''Phase III Trial Results Confirm Adjuvant Pertuzumab Success in HER2+ Breast Cancer''] - Could mention in ''History'' or a new ''Clinical trials'' section ? - [[User:Rod57|Rod57]] ([[User talk:Rod57|talk]]) 18:05, 20 March 2017 (UTC)